GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gufic Biosciences Ltd (BOM:509079) » Definitions » Equity-to-Asset

Gufic Biosciences (BOM:509079) Equity-to-Asset : 0.52 (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Gufic Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Gufic Biosciences's Total Stockholders Equity for the quarter that ended in Sep. 2024 was ₹5,742 Mil. Gufic Biosciences's Total Assets for the quarter that ended in Sep. 2024 was ₹11,047 Mil. Therefore, Gufic Biosciences's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.52.

The historical rank and industry rank for Gufic Biosciences's Equity-to-Asset or its related term are showing as below:

BOM:509079' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19   Med: 0.28   Max: 0.52
Current: 0.52

During the past 13 years, the highest Equity to Asset Ratio of Gufic Biosciences was 0.52. The lowest was 0.19. And the median was 0.28.

BOM:509079's Equity-to-Asset is ranked worse than
59.92% of 1043 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs BOM:509079: 0.52

Gufic Biosciences Equity-to-Asset Historical Data

The historical data trend for Gufic Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gufic Biosciences Equity-to-Asset Chart

Gufic Biosciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.44 0.52 0.40 0.49

Gufic Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 - 0.49 - 0.52

Competitive Comparison of Gufic Biosciences's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gufic Biosciences's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Gufic Biosciences's Equity-to-Asset falls into.



Gufic Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Gufic Biosciences's Equity to Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Equity to Asset (A: Mar. 2024 )=Total Stockholders Equity/Total Assets
=5325.605/10925.414
=0.49

Gufic Biosciences's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=5741.789/11046.704
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gufic Biosciences  (BOM:509079) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Gufic Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Gufic Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Gufic Biosciences Business Description

Traded in Other Exchanges
Address
SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral and a proton-pump inhibitor. It derives maximum revenue from India.

Gufic Biosciences Headlines

No Headlines